Tackling the Antibiotic Resistance Caused by Class A -Lactamases through the Use of -Lactamase Inhibitory Protein

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
aztreonam 2 infectiousdiseasesdrugs
cefotaxime 2 infectiousdiseasesdrugs
oxacillin 2 infectiousdiseasesdrugs
imipen 1 infectiousdiseasesdrugs
infectious disease 2 infectiousdiseases
meropenem 1 infectiousdiseasesdrugs
Ceftazidime 1 infectiousdiseasesdrugs
amoxicillin 1 infectiousdiseasesdrugs
cefepime 1 infectiousdiseasesdrugs
ceftriaxone 1 infectiousdiseasesdrugs
cephalothin 1 infectiousdiseasesdrugs
pneumonia 2 infectiousdiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Ceftazidime 23301 diaza-bicyclo octane (DABCO) core instead of the β-lactam core seen in tazobactam and sulbactam [[67],[68]]. Ceftazidime –avibactam was approved by the FDA in 2015 [[69]]. Avibactam inhibits many serine-β-lactamases, including
amoxicillin 21439 antibiotic counterpart. For example, the first BLI, clavulanic acid, is more potent when combined with amoxicillin . The inhibitors alter the substrates in their ability to assume long-lived, stable intermediates with
aztreonam 14668 NDM-1 is a novel metallo-β-lactamase that confers resistance to all β-lactams with the exception of aztreonam [[40]] and has been discovered recently in K. pneumoniae and E. coli [[41]]. Presently, NDM-1 resistant
aztreonam 17206 cefotetan), oxyimino cephalosporins (e.g., ceftazidime, cefotaxime and ceftriaxone) and monobactams (e.g., aztreonam ). However, the hydrolysis rates for cefepime, cefpirome and carbapenems are very low. Furthermore, AmpC
cefepime 17252 ceftazidime, cefotaxime and ceftriaxone) and monobactams (e.g., aztreonam). However, the hydrolysis rates for cefepime , cefpirome and carbapenems are very low. Furthermore, AmpC β-lactamases are not inhibited by EDTA or
cefotaxime 11366 the most common [[29],[30]]. Furthermore, CTX-M β-lactamases have high hydrolysis activity against cefotaxime and are capable of higher cephalothin hydrolysis in comparison to penicillins, cefaloxine and ceftazidime
cefotaxime 17155 including cephamycins (e.g., cefoxitin and cefotetan), oxyimino cephalosporins (e.g., ceftazidime, cefotaxime and ceftriaxone) and monobactams (e.g., aztreonam). However, the hydrolysis rates for cefepime, cefpirome
ceftriaxone 17170 cephamycins (e.g., cefoxitin and cefotetan), oxyimino cephalosporins (e.g., ceftazidime, cefotaxime and ceftriaxone ) and monobactams (e.g., aztreonam). However, the hydrolysis rates for cefepime, cefpirome and carbapenems
cephalothin 11403 Furthermore, CTX-M β-lactamases have high hydrolysis activity against cefotaxime and are capable of higher cephalothin hydrolysis in comparison to penicillins, cefaloxine and ceftazidime [[31]]. KPC can hydrolyze almost
imipen 13952 types of Class B β-lactamases, including VIM (Verona integron-encoded metallo-β-lactamase), IMP ( imipen emase) and NDM-1 (New Delhi metallo-β-lactamase). In the past, these enzymes were initially found to
meropenem 24997 boronic acid-based inhibitor, vaborbactam, was recently approved by the FDA in 2017 in combination with meropenem [[71]]. Additionally, other novel non β-lactam inhibitors, such as ZINC01807204 and ZINC02318494, have
oxacillin 9880 the ESBLs are of molecular Class A, with the exception of OXA-type enzymes (Class D β-lactamases or oxacillin ase) [[24]]. They are inhibited by β-lactamase inhibitors, such as clavulanic acid [[25]].2.1. Class
oxacillin 18821 hydrolyzed antibiotics [[52]].2.4. Class D β-LactamaseThe Class D enzymes or OXA-type β-lactamases ( oxacillin ases) are widely disseminated in Gram-negative bacteria [[53]]. The OXA encoded genes are found on both
Select Disease Character Offset Disease Term Instance
infectious disease 757 (collection): 8/2018Abstractβ-Lactams are the most widely used and effective antibiotics for the treatment of infectious disease s. Unfortunately, bacteria have developed several mechanisms to combat these therapeutic agents. One
infectious disease 4928 constituting 60% of worldwide antibiotic usage, and are among the most effective agents for treatment of infectious disease s [[9]]. They kill bacteria by inactivating the penicillin binding protein (PBP)-II, which represents
pneumonia 11134 Additionally, there are other types of class A β-lactamases, such as CTX-M (cefotaximase) and KPC (Klebsiella pneumonia e carbapenemase), that should be of great concern since they are widely spread and cause ESBL phenotypes,
pneumonia 14724 resistance to all β-lactams with the exception of aztreonam [[40]] and has been discovered recently in K. pneumonia e and E. coli [[41]]. Presently, NDM-1 resistant variants have spread globally, and bacterial isolates

You must be authorized to submit a review.